微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 55.32% | -4.65% | 0.1% | 67/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 55.26% | 0.35% | -4.43% | 63/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 57.82% | 4.72% | -2.26% | 56/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 59.16% | 5.33% | 1.97% | 55/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 58.01% | 9.84% | 5.35% | 55/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 55.07% | -7.29% | -0.27% | 67/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 55.21% | -9.93% | -1.68% | 65/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 56.16% | -9.49% | 6.33% | 65/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 52.82% | -13.14% | -11.08% | 70/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 59.4% | 3.14% | -3.11% | 56/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 61.3% | 3.2% | -1.2% | 51/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 62.05% | 2.69% | 2.04% | 52/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 60.81% | 1.73% | 5.59% | 52/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 57.59% | -1.35% | -3.05% | 65/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 59.4% | 2.13% | -1.69% | 56/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 60.43% | 3.7% | 1.09% | 56/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 59.77% | 2.88% | 2.39% | 58/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 58.38% | -5.04% | 0.37% | 65/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 58.16% | -7.7% | -0.18% | 56/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 58.27% | -8.87% | 0.29% | 59/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 58.1% | -10.8% | -5.49% | 55/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 61.48% | -14.95% | -2.44% | 56/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 63.01% | -12.65% | -1.46% | 48/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 63.95% | -10.29% | -1.83% | 44/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 65.14% | -5.33% | -9.88% | 34/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 72.28% | 0.96% | 0.19% | 34/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 72.14% | 1.8% | 1.21% | 24/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 71.28% | 2.52% | 3.6% | 26/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 68.8% | 2.57% | -3.9% | 23/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 71.59% | 13.27% | 1.03% | 32/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 70.86% | 14.81% | 1.92% | 20/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 69.52% | 14.97% | 3.65% | 20/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 67.07% | 15.67% | 6.12% | 27/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 63.21% | 11.19% | 2.41% | 37/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 61.72% | 10.49% | 2.06% | 27/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 60.47% | 7.69% | 4.29% | 28/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 57.99% | 6.47% | 2% | 26/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 56.85% | 2.84% | 1.77% | 37/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 55.86% | -1.27% | -0.53% | 24/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 56.16% | -5.27% | 3.11% | 27/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 54.46% | -4.32% | -1.47% | 22/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |